Market Overview: From Plant Compounds to Prescription Products

The cannabis pharmaceuticals market refers to the segment of the pharmaceutical industry focused on the development, manufacturing, and distribution of cannabis-based products for medical use. These products are derived from cannabis plants and include cannabidiol (CBD) and tetrahydrocannabinol (THC), and they are used to treat conditions such as chronic pain, epilepsy, and anxiety. Polaris Market Research values the market at USD 5.30 billion in 2024, projecting growth from USD 8.07 billion in 2025 to USD 357.96 billion by 2034 at a CAGR of 52.4%. North America was the largest market in 2024. Key drivers include increasing acceptance of cannabis for medical purposes, advances in research and clinical studies, and regulatory changes that facilitate its use in healthcare. Rising demand for non-psychoactive CBD products and the growing focus on personalized medicine are further shaping the market.

Growing Adoption of Medical Cannabis

The adoption of medical cannabis has expanded significantly across regions, driven by increasing evidence of therapeutic benefits. Cannabis-based treatments, particularly those containing CBD, have gained popularity for managing chronic pain, neurological disorders, and anxiety. Legalization in the US, Canada, and several European nations has boosted access. Polaris cites a 2023 study by the National Institute on Drug Abuse, which indicates that approximately 60% of medical cannabis users in the US report using it for pain management. This trend is expected to continue as more evidence validates the medical benefits of cannabis across therapeutic areas.

Non-Psychoactive CBD Products and Epidiolex

Non-psychoactive CBD products are becoming increasingly popular in the pharmaceutical market because they do not produce the high associated with THC. They have gained traction due to their perceived safety and effectiveness in epilepsy, insomnia, and anxiety. A significant milestone was the US FDA's approval of Epidiolex in 2018, the first cannabis-derived medication approved for treating certain types of epilepsy. Epidiolex holds the largest market share by brand type, supported by its clinical success, approval in multiple countries, and increasing acceptance among healthcare providers for neurological disorders. The brand is expected to keep dominating as more research supports its efficacy in other conditions.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/cannabis-pharmaceuticals-market

Investment and Clinical Trials Expand the Pipeline

As the legal landscape evolves, public and private investment in cannabis pharmaceutical research has increased markedly, driving innovation in new drugs and therapies. Research institutions and pharmaceutical companies are running clinical trials to explore efficacy in conditions such as cancer and Parkinson's disease. In 2021, the US National Institutes of Health allocated approximately USD 20 million in funding for cannabis research. The expanding body of clinical trials evidence is leading to more targeted and effective treatments. For new entrants, Polaris suggests focusing on evidence-backed, non-psychoactive products, research, and strong relationships with healthcare professionals.

Regional Strength and Market Challenges

North America holds the largest share of global revenue. In the US, the legalization of medical cannabis in several states has spurred significant growth, and approvals of cannabis-based drugs have facilitated broader adoption among healthcare providers and patients. A supportive regulatory environment and substantial investment in research continue to position the region as the dominant market. Europe is also growing steadily, though it lags North America in market size and speed of regulatory adoption. The report identifies stringent regulatory frameworks and high R&D costs as key restraints.

Key Players

•         Altria Group (parent company of Cronos Group)

•         Aphria (now part of Tilray)

•         Aurora Cannabis

•         Cannabis Science

•         Canopy Growth

•         Charlotte's Web

•         Cresco Labs

•         Green Thumb Industries

•         GW Pharmaceuticals (now part of Jazz Pharmaceuticals)

•         Hexo Corporation

•         MedReleaf

•         Organigram

•         Tilray

•         Tilray Health

•         Zynerba Pharmaceuticals

Conclusion

The cannabis pharmaceuticals market is expanding on the strength of medical acceptance, CBD-led innovation, and rising research investment. Valued at USD 5.30 billion in 2024 and projected to reach USD 357.96 billion by 2034 at a CAGR of 52.4%, it offers significant opportunity alongside regulatory and cost challenges. Stakeholders should concentrate on evidence-backed products, regulatory readiness, and partnerships with healthcare professionals to build credibility.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market